OL
SUPN icon

Odyssean LLC’s Supernus Pharmaceuticals SUPN Stock Holding History

Odyssean LLC’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$685K Sell
14,738
-12,852
-47% -$617K 0.11% 270
2026
Q1 		$1.43M Buy
27,590
+12,852
+87% +$654K 0.52% 39
2025
Q4 		$732K Buy
+14,738
New +$717K 0.53% 101

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Odyssean LLC's SUPN Position: Q2 2026 in Review

Odyssean LLC reduced its Supernus Pharmaceuticals (SUPN) stake by 47% in Q2 2026, selling an estimated $617K and leaving 14,738 shares worth $685K. The position accounts for 0.11% of the portfolio, ranked #270.

Odyssean LLC first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.43M in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Odyssean LLC held 14,738 shares of Supernus Pharmaceuticals worth $685K as of Q2 2026.
  • Odyssean LLC sold 12,852 Supernus Pharmaceuticals shares in Q2 2026, an estimated $617K.
  • Supernus Pharmaceuticals made up 0.11% of Odyssean LLC's portfolio in Q2 2026, its #270 holding.
  • Odyssean LLC first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Odyssean LLC's Supernus Pharmaceuticals position peaked at $1.43M in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Odyssean LLC's 13F filing for Q2 2026, filed 14 Aug 2026.